MedPage Today June 21, 2024
Diana Swift

— Emerging targets and treatment pathways in multiple myeloma

Although survival rates for patients with multiple myeloma are improving, with a 5-year rate of about 60%, many patients relapse after treatment.

“Patients have seen impressive advances in survival because of the widespread use of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation — all developed in the past 30 years,” said Andrew Cowan, MD, of Fred Hutch Cancer Center in Seattle. “However, with each successive line of therapy, we see attrition due to disease progression and other causes, so it is critical to use our best therapies early on to achieve optimal long-term outcomes.”

Already proving effective are B-cell maturation antigen (BCMA)-directed CAR T-cell therapies, including idecabtagene...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Pharma / Biotech
Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic
Ozempic Shortages Raise Questions About Prioritizing Access For Diabetics
Weight Loss Pills Intensify Obesity Drug Race—But Here’s Why Experts Say Injections Aren’t Going Anywhere
Podcast: New Alzheimer's Drug Approval Expands Treatment Options – and Creates Coverage Questions
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs

Share This Article